MoHAP and Bayer Middle East Sign MoU to Support MS and Hypertension Patients

Published Sunday, 29 December 2019

The Ministry of Health and Prevention, MoHAP, has recently signed a memorandum of understanding (MoU) with Bayer Middle East and Axios Health Education Services to provide a one-year medication for MS patients, patients with Pulmonary arterial hypertension (PAH), and patients with chronic thromboembolic pulmonary hypertension (CTEPH), whose medical insurance doesn’t cover the total cost of treatment.

The MoU is part of ‘Da’m’ initiative (Support) launched by MoHAP is 2018.

The agreement was signed at MoHAP headquarters by HE Dr. Amin Hussein Al Amiri, the Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, Henrik Wulff, Managing Director, Bayer Middle East, and Anas Al-Safarini, Executive Director for the Middle East and North Africa, Axios Health Education Services.

Supporting Needy Patients

Dr. Ruqaya Al Bastaki pointed to the importance of renewing the initiative for the second consecutive year, as part of MoHAP’s keenness on mitigating patient’s suffering, especially whose insurance is not covering the total cost of treatment and improve their commitment to the prescribed treatment plan.

The MoU also covers non-insured patients or those with partial insurance coverage.

Bolstering MoHAP’s Efforts

Henrik Wulff, Managing Director, Bayer Middle East, emphasized the company’s keenness on bolstering MoHAP’s efforts in providing MS patients, patients with Pulmonary arterial hypertension (PAH), and patients with chronic thromboembolic pulmonary hypertension (CTEPH) to ensure their adherence to treatment plans.

Facilitating Progress of the Program

Anas Al-Safarini, Executive Director for the Middle East and North Africa, Axios Health Education Services highlighted the importance of renewing the agreement, stressing Axios’s commitment to coordinate with charities and program partners to ensure the seamless progress of the program, in addition to managing patient’s treatment journey through the constant communication to ensure that they regularly receive the medication according to their treatment plan.

Did you find the content useful ?

Give us your feedback so we can improve your experience


Help us improve MOHAP website

Give us your feedback so we can improve your experience

Thank you for your feedback.